Click
Home
applytomedschoolbutton
AACOMmunities

Below is a selected list of timely federal funding opportunities that are relevant to the osteopathic medical education community. AACOM updates this resource frequently.  Please bookmark the page for your reference. For a comprehensive listing of federal funding opportunities, please visit Grants.gov.   

Featured Opportunities

May 13 – May 24

National Institute of Health

Digital Health Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)

Application Due: July 29, 2019

Letter of Intent: May 29, 2019

The purpose of this Funding Opportunity Announcement is to support research applications for commercializable, digital health-based products that aim at positively affecting the fundamental social and environmental conditions that are risk factors for the populations affected by the use of drugs, including opioids.

Centers Without Walls for Collaborative Research in the Epilepsies: Functional Evaluation of Human Genetic Variants (U54 Clinical Trial Not Allowed)

Application Due: August 27, 2019

Letter of Intent: July 27, 2019

The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement (U54) applications from multi-disciplinary groups of investigators to accelerate the rate of progress in determining the functional, pharmacological, neuronal network and whole animal consequences of genetic variants discovered in individuals with various types of epilepsy and to develop strategies for establishing diagnostic criteria and identifying potential targets for intervention.

Provocative Questions (PQs) in Multiple Myeloma Disparities Research (R01 Clinical Trial Optional)

Application Due: July 15, 2019

The National Cancer Institute (NCI) invites R01 applications for research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research identified as the NCI Multiple Myeloma Disparities Provocative Questions. These problems and paradoxes are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention.

Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)

Application Date: October 10, 2019

Letter of Intent: September 10, 2019

This Funding Opportunity Announcement uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying Substance Use Disorders (SUD), including fundamental brain function relevant to substance use.

PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional)

Application Deadline: November 8, 2019

Letter of Intent: October 8, 2019

NIDA is interested in research that addresses research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. There is a need to better understand the effects of substance use on PrEP effectiveness and better inform PrEP implementation among substance users. More systematic data are needed regarding the impact of substance use on PrEP management and adherence, along with investigating potential unintended consequences of PrEP use that may be unique to substance users such as changes in harm reduction practices, as well as substance use as a contributor to health risk behaviors with consequences such as increased occurrence of STIs.

Workshops on the Use of Adolescent Brain Cognitive Development (ABCD) Data (R25 Clinical Trial Not Allowed)

Application Due: October 17, 2019

Letter of Intent: September 1, 2019

The over-arching goal of this NIDA/NIMH R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs in the use of ABCD data. To accomplish the stated over-arching goal, this funding opportunity will support creative educational activities with a primary focus on Courses for Skills Development. In particular, NIDA/NIMH are interested in supporting short-term workshops that will allow participants to explore the hands-on use of ABCD data, through cooperative or competitive approaches.

Limited Competition: NIA Genome Center for Alzheimer's Disease (GCAD) (U54 Clinical Trial Not Allowed)

Application Due:

Letter of Intent: August 25, 2019

This Funding Opportunity Announcement invites applications to continue the operations of the NIA Genome Center for Alzheimer's Disease (GCAD) to facilitate and support the Alzheimer's Disease Sequencing Project (ADSP) activities. GCAD will serve as the focal point for all phases of ADSP quality control checking, data harmonization, and meta-analysis.

Understanding Senescence in Brain Aging and Alzheimer's Disease (R01 Clinical Trial Not Allowed)

Application Due: October 17, 2019

Letter of Intent: September 17, 2019

The goal of this funding opportunity is to support research focused on understanding the role of senescence in brain aging and in Alzheimer's disease. This grant encourages research projects addressing critical knowledge gaps in our understanding of the neurobiology of senescence through cutting-edge techniques, cross-disciplinary collaborations, and/or conceptual innovation, leveraging what is known about senescence in peripheral tissues to learn more about brain aging. Developing a clear understanding of the mechanisms driving aging processes in the brain, including senescence, is essential for combating age-related neurodegenerative diseases.
 

April 29–May 10

National Institutes of Health

HLA and KIR Region Genomics in Immune-Mediated Diseases (U19 Clinical Trial Not Allowed)

Letter of Intent Due: August 4, 2019

Application Due: September 4, 2019

Supports projects defining the association between variations in the human leukocyte antigen, also known as the Major Histocompatibility Complex, and natural killer cell immunoglobulin-like receptor genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and organ transplantation.

Cognitive Systems Analysis of Alzheimer’s Disease Genetic and Phenotypic Data (U01 Clinical Trial Not Allowed)

Letter of Intent Due: September 5, 2019

Application Due: October 5, 2019

This Funding Opportunity Announcement invites applications that propose Artificial Intelligence, Machine Learning, and/or Deep Learning  approaches, collectively referred to here as "cognitive systems," that lead to the identification of gene mutations/variants that cause or contribute to the risk of or protection against the development of Alzheimer’s disease and Alzheimer's disease related dementias via analysis of a variety of genetic, genomic, and biomarker data that are currently available to the research community.

Dissemination and Implementation Research in Health (R01)  

Letter of Intent: June 5, 2019

Application Deadline: July 5, 2019

This funding opportunity encourages investigators to submit research grant applications that will identify, develop, test, evaluate and/or refine strategies to disseminate and implement evidence-based practices (e.g. behavioral interventions; prevention, early detection, diagnostic, treatment and disease management interventions; quality improvement programs) into public health, clinical practice, and community settings.